PRESS RELEASE

BioRelix Enters Antibacterial Collaboration
with Merck

NEW HAVEN, CONNECTICUT, October 4, 2010 – BioRelix, Inc. today announced that it has entered into a research collaboration agreement with a subsidiary of Merck & Co., Inc. to identify new antibacterial drug candidates.

Under the agreement, BioRelix will apply its proprietary riboswitch technology platform to identify compounds with activity against a number of bacterial targets. The parties will jointly undertake preclinical programs, and Merck will subsequently be responsible for clinical evaluation of any candidates chosen for further development. Merck will pay BioRelix an upfront fee and provide research funding. In addition, BioRelix is eligible to receive payments upon achievement of specified milestones associated with advancement of drug candidates and royalties on the sales of any products derived from the collaboration.

"There is a tremendous patient need for new agents against difficult to treat and drug resistant infections," stated Brian Dixon, Chief Executive Officer of BioRelix. "We’re delighted to combine our technology with such a capable partner in order to provide new mechanisms and new chemistry to fight these life threatening diseases.”

"Collaborations with companies like BioRelix are essential as we seek to apply the latest innovative drug discovery technologies towards the discovery of new much needed antibacterial medications," said Roger Pomerantz, MD, senior vice president, and Global Franchise Head, Infectious Diseases, Merck Research Laboratories.

About BioRelix

BioRelix, Inc, is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, Novartis Venture Funds, Aisling Capital, New Leaf Venture Partners, Elm Street Ventures and Alexandria Real Estate Equities, Inc.

<< Previous Press Release| Next Press Release >>

At Merck, flexibility, innovation and creativity are at the heart of the way we work with partners around the world.

Our Licensing team works with partners to advance their science through drug discovery and development collaborations and licensing agreements that are mutually beneficial.

Our Commercial Partnerships team pursues business opportunities with partners to jointly deliver their products and ours to the marketplace.

TRUSTe - Click to Verify   This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.